natural pharmaceuticals derived From Cannabis and other medicinal plants
Recently Received Notice of Authorization from Health Canada for the Conduct of its Clinical Trial with its PPTGR topical product
Message: Tetra Bio-Pharma Provides USA Regulatory Update for its Cannabis Inhalation Product PPP001
OTTAWA, ONTARIO--(Nov. 23, 2016) - PhytoPain Pharma Inc. ("PPP"), a subsidiary of Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE:TBP) (CSE:TBP.CN) (OTC PINK:GRPOF), is a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain and other medical conditions announces that the development of its smoked marijuana prescription drug is on schedule.
The Company confirmed that, on November 8, 2016, it received a letter from the Office of Combination Products stating that the USA Food and Drug Administration ("FDA") had completed its review of the request for designation for the marijuana prescription drug and titanium pipe kit. The FDA confirmed that the product is a combination product, and assigned it to the Center for Drug Evaluation and Research ("CDER") as the lead agency center for premarket review and regulation based on FDA's determination of the marijuana product's primary mode of action.
The Company previously announced that it received a pre-IND (Investigational New Drug) acknowledgement and meeting request granted letter from the US FDA. This week, the company is submitting the information package required by FDA for the Type B pre-IND meeting in January 2017 with the Division of Anesthesia, Analgesia, and Addiction Products, Center for Drug Evaluation and Research. According to Dr. G. Chamberland, Chief Science Officer, "As per FDA policies, the pre-IND information package is submitted to obtain guidance from FDA on the product development and marketing requirements for the smoked marijuana prescription drug combination product". Dr. Chamberland further commented that this regulatory filing is part of PPP's dedication to the commercialization of marijuana as a prescription controlled drug and the corporation's plan to seek reimbursement by insurers for patients.
The Company has been working with Algorithme Pharma, an Altasciences company, for the conduct of its Phase I clinical trial in healthy human subjects. PPP is using the services of Algorithme Pharma based on its experience and expertise in the conduct of clinical trials for the pharmaceutical industry. Later this week the project team will be submitting the Phase I clinical protocol, and related documents, to the Institutional Review Board for review. If approved, Algorithme Pharma will subsequently submit the Clinical Trial Application to the Therapeutic Products Directorate of Health Canada for approval. In parallel, Algorithme Pharma will submit an application for exemption under section 56 of the Controlled Drugs and Substances Act for its planned research on healthy subjects.
The Company stated that, subsequent to a request for classification to the Medical Devices Bureau, Health Canada, the PPP001-titanium pipe that will be used in the clinical trial is a Class I medical device. Dr. Chamberland commented: "As a Class I medical device, the PPP001-titanium pipe does not require approval for use in the clinical trial".
About PPP001-kit product
PPP001-kit product will be sold as two separate products packaged together in a single package and is comprised of the drug PPP001 and the device PPP001-titanium pipe. The drug component and device component will be linked together by the labelling of each component.
The product PPP001-kit, once approved, could be sold in pharmacies containing the prescription controlled drug PPP001, in a blister pack, and the PPP-titanium pipe device that will be used to generate the smoke to deliver the active ingredients by inhalation.
PPP001 drug pellet blisters and a fully assembled PPP-titanium pipe for combustion and inhalation of the generated smoke are required for therapy with PPP001 and are provided in the PPP001-kit.
Each blister of PPP001 drug pellet contains marijuana with a standardized amount of delta-9-tetrahydrocannibinol and cannibidiol. A single PPP001 drug pellet is pushed out of the blister by the patient and inserted into the PPP-titanium pipe.
In Other News:
The Company has received $227,738 in exercised warrants for November 2016.
The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Bio-Pharma Inc.
Ryan Brown - VP Business Development and Communications
Andre Audet - Executive Chairman
Dr. Guy Chamberland - Chief Scientific Officer
Please login to post a reply